Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
561 hedge funds and large institutions have $26B invested in Alexion Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 85 funds opening new positions, 220 increasing their positions, 204 reducing their positions, and 62 closing their positions.
37% more first-time investments, than exits
New positions opened: 85 | Existing positions closed: 62
2% more funds holding
Funds holding: 548 → 561 (+13)
8% more repeat investments, than reductions
Existing positions increased: 220 | Existing positions reduced: 204
1% more call options, than puts
Call options by funds: $263M | Put options by funds: $260M
3% less capital invested
Capital invested by funds: $26.9B → $26B (-$933M)
29% less funds holding in top 10
Funds holding in top 10: 24 → 17 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.32B |
| 2 |
JP Morgan Chase
New York
|
+$175M |
| 3 |
Jennison Associates
New York
|
+$174M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$128M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$122M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$922M |
| 2 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$275M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$232M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$150M |
| 5 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$134M |
ALXN Hedge Fund Activity: Q1 2017 in Review
561 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q1 2017, worth a combined $26B — down 3.5% from $26.9B a quarter earlier.
Buyers outnumbered sellers: 85 funds opened new ALXN positions and 62 closed out — a net gain of 23 holders — while 220 added to existing stakes and 204 trimmed.
The largest buyer was BlackRock, adding an estimated $2.32B. The largest seller was Capital Research Global Investors, cutting an estimated $922M.
- 561 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q1 2017, up from 548 in Q4 2016.
- Funds reported $26B of Alexion Pharmaceuticals stock for Q1 2017, down 3.5% quarter-over-quarter.
- 85 funds opened new Alexion Pharmaceuticals positions in Q1 2017 and 62 closed out, a net change of +23 holders.
- The largest Alexion Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $2.32B added.
- The largest Alexion Pharmaceuticals seller in Q1 2017 was Capital Research Global Investors, an estimated $922M sold.
Based on aggregated 13F filings for Q1 2017.